The frequency of early complications after allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative (MA) and non-myeloablative (NMA) conditioning regimen

Allogeneic hematopoietic stem cell transplantation after immunosuppressive but non-myeloablative conditioning: "miniallografts" are no small matter.

Pemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning.

OBJECTIVES Successful treatment of severe, refractory Pemphigus vulgaris (PV) is reported. METHODS Reduced intensity, non-myeloablative conditioning was employed, followed by allogeneic hematopoietic stem cell transplantation (HSCT) from a fully matched sibling. RESULTS Treatment of refractory PV with myeloablation and subsequent allogenic HSCT has been previously reported, and sustained re...

Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.

Allogeneic hematopoietic stem cell transplantation (HSCT) following myeloablative (conventional) conditioning regimen is associated with a high incidence of transplant-related morbidity and mortality, limiting its use to younger patients without medical co-morbidities. Over the past few years, it has become more evident that the alloreactivity of transplanted donor immunocompetent cells against...

Prevalence of chimerism after non-myeloablative hematopoietic stem cell transplantation.

CONTEXT AND OBJECTIVE Non-myeloablative hematopoietic stem cell transplantation (NMA-HSCT) is performed in onco-hematological patients who cannot tolerate ablative conditioning because of older age or comorbidities. This approach does not completely eliminate host cells and initially results in mixed chimerism. Long-term persistence of mixed chimerism results in graft rejection and relapse. Inv...

Stem cell transplantation using non-myeloablative conditioning regimen with fludarabine for hematological malignancies.

Stem cell transplantation (SCT) is a useful treatment for hematological malignancies, but it is limited to younger patients because of its high treatment-related mortality. Fludarabine (Flu), a novel anticancer agent with potent immunosuppressive activity, used as a conditioning regimen (reduced intensity transplantation; RIST), can decrease treatment-related mortality, as recently reported. Ho...